Glacier Energy Services Holdings Limited is a leader in the design and manufacture of precision on-site portable cutting machines and a specialist provider of weld overlay and cladding services to the oil and gas industry. Website: www.glacier.co.uk.
Glacier is one of the companies that has received investment from the Simmons Parallel Energy Fund.
Aurora invested in 2009 and the fund is now closed to new subscriptions. Administered under the auspices of Simmons International, the fund is focused on buy-out and growth capital opportunities through minority co-investments in private companies and private placements for publicly listed stocks in Europe and the Eastern Hemisphere with independent investors, industry investors and private equity firms. Website: www.simmonsco-intl.com/About-Us/Parallel-Energy-Fund
The Fund’s portfolio companies are:
Electro-flow Control Group Limited provides drilling and marine instrumentation products globally predominately to the rig upgrade market. It also provides product guidance systems and onshore, subsea, nuclear and renewables handling and lifting. Website: www.efcgroup.net
Flexlife Group Limited provides integrity management and engineering services for flexible risers and pipelines and also provides subsea engineering and project management services. Website: www.flexlife.co.uk
Xodus Group Limited provides engineering, subsurface, safety and environmental services to the global upstream oil and gas industry. Website: www.xodusgroup.com
Glacier Energy Services Holdings Limited is a leader in the design and manufacture of precision on-site portable cutting machines and a specialist provider of weld overlay and cladding services to the oil and gas industry. Website: www.glacier.co.uk
NovaBiotics is a leading clinical stage biotechnology company focused on the design and development of first-in-class anti-infective therapies for difficult to treat, poorly served infectious conditions.
Cytosystems Ltd, a Scottish-based company, has developed unique urine-based screening and diagnostic solutions to detect cancer of the bladder. Specificity and sensitivity are both 98%. comprising:
The tests can replace invasive, distressing and expensive endoscopic test procedures. Independent research has confirmed that successfully introducing a nurse-managed diagnostic solution of this type into the clinic could enable earlier, more accurate diagnosis, improve patient care, enhance outcomes and greatly reduce associated healthcare costs by as much as 50%.
The core MCM technology was developed over a twelve-year period by Cancer Research UK at Cambridge University.